Last updated: September 25, 2026
Chlordiazepoxide hydrochloride/clidinium bromide is an old, low-growth combination product marketed primarily as Librax. The product contains a benzodiazepine, chlordiazepoxide hydrochloride 5 mg, and an anticholinergic, clidinium bromide 2.5 mg, in an oral capsule. Its commercial position is constrained by generic competition, limited contemporary guideline use, controlled-substance restrictions, and the availability of alternative gastrointestinal therapies.
The product has no meaningful remaining composition-of-matter exclusivity. Commercial value is concentrated in residual prescriptions, brand recognition, manufacturing continuity, and physician familiarity rather than patent protection. Public companies do not separately disclose material revenue for the combination, so product-level sales and profit cannot be calculated reliably from SEC filings.
What is chlordiazepoxide hydrochloride and clidinium bromide used for?
Chlordiazepoxide/clidinium bromide is indicated as an adjunct in the treatment of peptic ulcer disease and irritable bowel syndrome. The product combines:
| Component |
Pharmacologic role |
Key commercial implication |
| Chlordiazepoxide hydrochloride |
Benzodiazepine with anxiolytic and sedative effects |
Creates controlled-substance, dependence, abuse, and withdrawal exposure |
| Clidinium bromide |
Anticholinergic agent that reduces gastrointestinal smooth-muscle activity and secretions |
Creates anticholinergic tolerability and geriatric-use limitations |
| Combination capsule |
Fixed-dose gastrointestinal product |
Provides convenience but has limited differentiation from modern alternatives |
The FDA-approved labeling states that the combination is used as an adjunct rather than as a first-line treatment for most gastrointestinal disorders. The label also carries benzodiazepine warnings concerning abuse, misuse, addiction, physical dependence, and withdrawal reactions. Older adults face increased risks from sedation, confusion, falls, and anticholinergic effects. [1]
The product is commonly associated with the Librax brand, although generic versions have been marketed under the active-ingredient names. Prescribing demand is concentrated in gastrointestinal and primary-care settings, with a smaller contribution from physicians treating functional bowel symptoms.
How large is the chlordiazepoxide/clidinium bromide market?
The U.S. market is a mature, low-volume prescription market with limited growth potential. Public sources do not provide a reliable standalone revenue figure for the active-ingredient combination. Manufacturer filings generally aggregate the product into broader portfolios or do not identify it as material revenue.
Market characteristics include:
- Long-established clinical use dating to the early era of combination gastrointestinal products.
- Generic availability and low barriers to therapeutic substitution.
- Limited inclusion in contemporary treatment algorithms for irritable bowel syndrome.
- Demand from a persistent but narrow prescriber base.
- Price competition among generic suppliers.
- Brand-price premiums that depend on reimbursement and supply conditions.
- Low probability of substantial prescription growth without a new indication or reformulation.
The commercial market is better described as a maintenance or tail market than as a growth asset. Revenue can remain stable for a supplier with dependable manufacturing and distribution, but the product has little intrinsic ability to expand its addressable population.
What drives demand for Librax and generic equivalents?
Demand is supported by several factors:
- Physician familiarity with the product.
- Patients who report prior benefit or prefer an established capsule.
- Use in selected functional gastrointestinal conditions.
- Limited direct substitution in patients whose prescribers want both an antispasmodic and a benzodiazepine in one product.
- Intermittent shortages or supply disruptions affecting competing suppliers.
Demand is limited by:
- Benzodiazepine prescribing controls.
- FDA warnings on dependence and withdrawal.
- Anticholinergic risks.
- Availability of nonbenzodiazepine antispasmodics.
- Proton-pump inhibitors and H2-receptor antagonists for acid-related disease.
- Increasing preference for targeted therapies in irritable bowel syndrome.
- Payer pressure favoring generic monotherapies or newer guideline-supported products.
What is the FDA regulatory status of chlordiazepoxide/clidinium bromide?
Chlordiazepoxide is a Schedule IV controlled substance under the federal Controlled Substances Act. The combination therefore carries controlled-substance prescribing, dispensing, recordkeeping, and state-law compliance requirements. [2]
Librax is an FDA-approved prescription drug. The product label identifies the formulation as capsules containing 5 mg of chlordiazepoxide hydrochloride and 2.5 mg of clidinium bromide. The FDA labeling includes contraindications and warnings related to glaucoma, urinary retention, prostatic hypertrophy, myasthenia gravis, respiratory depression, pregnancy-related risks, and benzodiazepine dependence. [1]
The FDA has also required class-wide boxed-warning updates for benzodiazepines. The 2020 communication addressed risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions across the benzodiazepine class. [3]
Is the product a biologic or a biosimilar risk?
No. Chlordiazepoxide hydrochloride/clidinium bromide is a synthetic small-molecule combination product. Biosimilar competition is not relevant. The competitive risks are conventional generic entry, additional abbreviated new drug applications, authorized-generic strategies, manufacturing interruptions, and therapeutic substitution.
What patents protect chlordiazepoxide hydrochloride and clidinium bromide?
The original product and its active ingredients are decades old. Any original composition-of-matter, formulation, or basic combination patents would have expired long ago. The commercial product does not depend on a current patent monopoly.
| IP category |
Current commercial relevance |
| Chlordiazepoxide composition patents |
Expired |
| Clidinium bromide composition patents |
Expired |
| Original fixed-dose combination protection |
Expired |
| Core capsule formulation patents |
Expired or commercially irrelevant |
| Method-of-use patents |
No material exclusivity identified for the marketed indication |
| Manufacturing patents |
Unlikely to block routine generic production |
| Brand trademarks |
May remain enforceable but do not prevent generic substitution |
The absence of meaningful patent protection shifts competition toward regulatory approvals, supplier reliability, manufacturing economics, distribution access, and reimbursement.
What is the Orange Book status of Librax?
The FDA Orange Book is the principal source for identifying approved drug products, therapeutic-equivalence evaluations, and certain listed patents and exclusivities. For an old combination such as Librax, the commercial question is whether any active patent or regulatory exclusivity remains listed against the reference product.
No commercially meaningful patent barrier is expected to remain for the marketed combination. Any Orange Book listing associated with the product should be verified against the current FDA Orange Book entry because listing status, discontinued-product records, and approved supplier information can change over time. [4]
The relevant regulatory pathway for competing products is generally an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product, rather than a 505(b)(2) strategy or biologics pathway.
When did chlordiazepoxide/clidinium bromide lose exclusivity?
The product lost meaningful exclusivity decades ago. The original combination entered the market in the 1960s, and any statutory exclusivity associated with the original approval has long expired. The product is therefore in the post-exclusivity phase of its lifecycle.
Exclusivity timeline
| Period |
Event |
Market effect |
| 1960s |
Original Librax-era approval and commercialization |
Establishment of the combination product |
| Subsequent decades |
Expiration of original patent and regulatory protections |
Opening of the market to generic competition |
| 1990s-2000s |
Continued generic and branded availability |
Erosion of pricing power |
| 2010s |
Greater focus on benzodiazepine safety and controlled-substance risks |
Reduced prescribing attractiveness |
| 2020 |
FDA class-wide benzodiazepine boxed-warning update |
Higher compliance and risk-management burden |
| Current market |
Mature generic market |
Low growth, limited patent-driven value |
There is no credible basis for a new patent-term extension or pediatric exclusivity strategy for the legacy combination absent a new, independently approved product or indication.
Are there Paragraph IV challenges against Librax?
Paragraph IV litigation is not a central current issue for this product. Paragraph IV certifications apply when an ANDA applicant challenges a listed patent as invalid, unenforceable, or not infringed. Because the product’s relevant patent estate is old and commercially weak, generic competition is more likely to proceed through ordinary ANDA approval than through high-value patent litigation.
No major, publicly visible, current Paragraph IV campaign is associated with Librax comparable to litigation involving high-revenue branded medicines. The absence of prominent litigation is itself consistent with the product’s low commercial value and expired core IP.
A generic applicant could still raise patent-listing or certification issues if an active listing appeared in the Orange Book, but the economic incentive to litigate would be limited unless the applicant expected substantial market share or a supply-constrained market.
What formulations are protected by chlordiazepoxide/clidinium bromide patents?
The commercially established formulation is an immediate-release oral capsule. No active formulation patent is known to provide durable exclusivity around the standard 5 mg/2.5 mg capsule.
Potential formulation strategies could include:
- Modified-release capsules.
- Lower-dose products intended to reduce benzodiazepine exposure.
- Alternative delivery systems.
- A clidinium-only formulation.
- A nonbenzodiazepine gastrointestinal combination.
These strategies would require new clinical, regulatory, and commercial justification. A reformulation would not automatically preserve the market for the existing product, and a new patent would face obviousness, written-description, enablement, and clinical-value challenges.
What patent litigation affects Librax?
No material current patent litigation is publicly associated with the core Librax product. The litigation risk profile is therefore low compared with newer branded drugs.
The main legal risks are more likely to involve:
- Controlled-substance prescribing and dispensing compliance.
- Product liability claims related to sedation, dependence, withdrawal, falls, or anticholinergic injury.
- Manufacturing and quality complaints.
- Trademark disputes involving brand presentation.
- Contract disputes between manufacturers, distributors, and pharmacies.
These risks do not create exclusivity. They can increase operating costs and reduce the attractiveness of the product to smaller suppliers.
Which companies are challenging or competing with Librax?
Competition comes from generic suppliers and therapeutic substitutes rather than from a single branded challenger.
Direct generic competition
Generic products may be sold under labels such as chlordiazepoxide hydrochloride and clidinium bromide capsules. The identity of active suppliers can change because older generic products are intermittently discontinued, transferred, or relaunched. FDA approval records and current commercial listings are the appropriate sources for supplier verification. [5]
Therapeutic competitors
| Competitive category |
Examples |
Competitive effect |
| Antispasmodics |
Dicyclomine, hyoscyamine |
Compete for bowel-spasm and functional GI use |
| Acid-suppression products |
Omeprazole, pantoprazole, famotidine |
Compete in peptic-ulcer and acid-related disease |
| IBS-directed therapies |
Linaclotide, plecanatide, rifaximin, lubiprostone |
Compete for defined IBS subtypes |
| Nonpharmacologic management |
Dietary intervention, behavioral therapy |
Reduces demand in functional GI disorders |
| Other sedating therapies |
Various benzodiazepines and adjunctive agents |
Compete for symptom relief but carry similar safety concerns |
Librax is disadvantaged when physicians prefer to avoid benzodiazepines or separate treatment of gastrointestinal symptoms from anxiety and sedation.
How strong is the patent estate for chlordiazepoxide/clidinium bromide?
The patent estate is weak from a commercial protection standpoint.
| Factor |
Assessment |
| Core patent age |
Very old |
| Remaining patent term |
No meaningful term expected |
| Orange Book leverage |
Low |
| Formulation differentiation |
Limited |
| Method-of-use protection |
No material current barrier identified |
| Generic substitution risk |
High |
| Litigation value |
Low |
| Manufacturing complexity |
Low to moderate |
| Supply-chain sensitivity |
Potentially meaningful |
The product can still generate cash flow for a low-cost supplier, but the asset is not attractive as a patent-protected investment. Its value depends on operating execution rather than intellectual property.
What is the financial trajectory for Librax and generic chlordiazepoxide/clidinium bromide?
The financial trajectory is likely flat to declining in nominal prescription demand, with occasional periods of price volatility caused by supplier exits or shortages.
Revenue outlook
| Financial driver |
Expected direction |
Rationale |
| Prescription volume |
Flat to declining |
Mature indication and limited guideline momentum |
| Average selling price |
Low, with episodic volatility |
Generic competition and reimbursement pressure |
| Gross margin |
Supplier-dependent |
Can improve during shortages but compress under competition |
| Brand premium |
Narrow and payer-dependent |
Generic substitution limits pricing |
| R&D requirement |
Low for existing product |
No major development program needed |
| Regulatory burden |
Increasing |
Benzodiazepine warnings and controlled-substance compliance |
| Product lifecycle |
Late stage |
No realistic organic growth platform |
For a manufacturer with an approved product and stable supply, the combination may produce recurring but modest revenue. For an investor, the product is more likely to fit a portfolio of mature generic medicines than a standalone growth thesis.
Revenue exposure for manufacturers
Large diversified pharmaceutical companies are unlikely to disclose material product-level exposure. The combination’s revenue would generally be immaterial relative to oncology, immunology, diabetes, cardiovascular, or specialty-care portfolios.
The asset can have strategic value in three circumstances:
- A manufacturer has low-cost access to the active ingredients and capsule manufacturing.
- Competitor supply is disrupted.
- The product is bundled with a broader gastrointestinal or generic portfolio.
Absent those conditions, the product has limited licensing value.
What generic launch scenarios exist?
Base case: continued low-price generic supply
Multiple approved or previously approved suppliers continue serving a small market. Prices remain low, and no significant patent litigation occurs.
Downside case: supplier consolidation
One or more manufacturers exit because of low margins, compliance costs, or active-pharmaceutical-ingredient constraints. Reduced competition can create temporary price increases and pharmacy-level shortages, but it does not create durable exclusivity.
Upside case: authorized or branded supply disruption
A manufacturer captures short-term share after a competitor experiences a manufacturing interruption. The gain is operational rather than patent-driven and may reverse when supply normalizes.
Limited-growth case: reformulation or new indication
A new formulation could create temporary differentiation, but it would require clinical evidence, FDA approval, and a safety rationale strong enough to overcome benzodiazepine-related concerns. This scenario is commercially unlikely for the legacy combination.
How does Librax compare with modern gastrointestinal medicines?
Librax has a low-cost, familiar fixed-dose format but a weaker contemporary clinical and regulatory position.
| Attribute |
Librax |
Modern targeted GI therapies |
| Patent protection |
Expired |
Often active |
| Generic competition |
High |
Often limited before patent expiry |
| Benzodiazepine exposure |
Yes |
Usually no |
| Anticholinergic exposure |
Yes |
Product-dependent |
| Reimbursement |
Generally low-cost |
Higher for branded agents |
| Guideline momentum |
Limited |
Stronger in defined patient populations |
| Commercial growth |
Low |
Can be substantial before loss of exclusivity |
| Safety perception |
Challenged by dependence and anticholinergic risks |
Depends on mechanism |
What licensing deals involve chlordiazepoxide/clidinium bromide?
No major recent licensing transaction is publicly associated with the combination. The product’s age, generic status, and limited revenue base reduce the likelihood of a material standalone licensing deal.
Potential transactions would more likely involve:
- Acquisition of an ANDA or approved product line.
- Transfer of manufacturing rights.
- Portfolio purchases involving multiple mature generics.
- Distribution agreements.
- Brand or trademark rights connected to Librax.
A standalone licensing deal would generally require a supply, geographic, or distribution rationale rather than patent value.
What geographic markets are commercially relevant?
The United States is the most visible regulatory and commercial market because Librax has an established FDA-approved product and a recognized generic pathway. International availability varies by country because of differences in:
- Benzodiazepine scheduling.
- Anticholinergic classification.
- Brand registration.
- Local generic approvals.
- Reimbursement.
- Prescribing restrictions.
- Distribution controls.
The combination should not be treated as a globally uniform asset. A product can remain available in one jurisdiction while being discontinued, unregistered, or commercially irrelevant in another.
Key Takeaways
- Chlordiazepoxide hydrochloride/clidinium bromide is a mature Librax-associated gastrointestinal combination.
- The standard product contains 5 mg of chlordiazepoxide hydrochloride and 2.5 mg of clidinium bromide per capsule.
- Core patent and regulatory exclusivity expired decades ago.
- No meaningful current patent barrier or major Paragraph IV litigation is associated with the product.
- Biosimilar risk does not apply because the product is a synthetic small-molecule combination.
- Generic competition, benzodiazepine warnings, anticholinergic risks, and modern GI alternatives constrain demand.
- Product-level revenue is not separately disclosed by major manufacturers.
- The financial profile is recurring but low-growth, with possible temporary price increases during supply disruptions.
- Commercial value depends on manufacturing reliability, distribution, and portfolio economics rather than intellectual property.
- The most credible investment thesis is a mature-generic cash-flow or supply-constrained opportunity, not a patent-driven growth asset.
FAQs
Is Librax still FDA approved?
Yes. Librax is an FDA-approved prescription capsule containing chlordiazepoxide hydrochloride and clidinium bromide. Current labeling and marketing status should be checked through FDA Drugs@FDA and the current product label. [1]
Is chlordiazepoxide/clidinium bromide a controlled substance?
Yes. Chlordiazepoxide is a Schedule IV benzodiazepine. The product is subject to controlled-substance prescribing and dispensing requirements. [2]
Can a generic manufacturer launch chlordiazepoxide/clidinium bromide without a patent settlement?
Yes, if the relevant ANDA pathway is satisfied and no enforceable blocking patent remains. The old age of the product reduces the likelihood that a settlement would be necessary.
Does Librax have a meaningful patent cliff?
No. The principal patent cliff occurred decades ago. Current commercial changes are more likely to result from supplier exits, reimbursement changes, or manufacturing interruptions.
Is chlordiazepoxide/clidinium bromide attractive for pharmaceutical licensing?
Usually not as a standalone IP asset. It may have value in a mature-generic portfolio, an authorized-generic arrangement, or a regional distribution transaction, but its expired patent estate limits licensing leverage.
References
-
U.S. Food and Drug Administration. (n.d.). Librax: Chlordiazepoxide hydrochloride and clidinium bromide capsules prescribing information. Drugs@FDA.
-
U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. U.S. Department of Justice.
-
U.S. Food and Drug Administration. (2020, September 23). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. FDA Drug Safety Communication.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
